- Full-scale entry into the world's fourth largest antiulcer drug market with fast action, ease of administration, and long half-life
- Aiming to enter 100 countries by 2027…Accelerating toward the '1 product, KRW 1 trillion' goal by 2030
[by Ji, Yong Jun] Daewoong Pharmaceutical has announced the launch of 'Fexuclue' in India, marking the company’s full-scale entry into the world's fourth-largest antiulcer drug market. This launch represents the first instance of a domestically developed potassium-competitive acid blocker (P-CAB) drug introduced in the Indian market. The approved indication for Fexuclue is erosive gastroesophageal reflux disease (GERD).
Daewoong Pharmaceutical announced on April 7 that it has officially launched 바카라 사이트 in the Indian market. Developed as a third-generation treatment for gastroesophageal reflux disease (GERD), 바카라 사이트 was first introduced by the company in 2022. The drug is anticipated to rapidly gain market share in India’s antiulcer sector by addressing the limitations of existing PPIs (proton pump inhibitors), such as delayed onset of action, short half-life, and the requirements for administration prior to meals.
According to 2023 data from the global market research firm IMS, India ranks as the fourth largest antiulcer drug market in the world, following China, the United States, and Japan, with an annual market size of around KRW 1.4 trillion (approximately USD 951.7 million). Daewoong Pharmaceutical designated India as a key strategic base for the global expansion of 바카라 사이트 and signed a technology transfer agreement in December 2023 with Sun Pharma Laboratories Ltd., the No. 1 pharmaceutical company in India. The company noted that it achieved rapid local market entry by efficiently moving from product approval application to official launch.
Sun Pharma conducted a Phase 3 clinical trial of 바카라 사이트 in patients with erosive GERD, recruiting participants locally in India. The trial results demonstrated 바카라 사이트’s non-inferiority to the PPI drug 'Esomeprazole' in terms of 8-week and 4-week treatment rates, while also showing improvements in key symptoms. Based on the outcomes, 바카라 사이트 received product approval from India’s Central Drugs Standard Control Organization (CDSCO).
Daewoong Pharmaceutical has expanded the global reach of 바카라 사이트 to six countries, including Korea, Mexico, Chile, Ecuador, the Philippines, and now India. In addition, the company has applied for product approval in 19 other countries and signed export contracts with five more, bringing the total number of countries to 30. Daewoong Pharmaceutical is accelerating its overseas expansion with the ambitious goal of entering 100 countries by 2027. As of 2024, 바카라 사이트 surpassed KRW 100 billion in annual sales, achieving this milestone within just three years of its initial launch.
“With this launch, we are confident that 바카라 사이트 will become a groundbreaking treatment option for patients suffering from gastroesophageal reflux disease in India, the world’s fourth-largest antiulcer drug market,” stated Park Seong-soo, CEO of Daewoong Pharmaceutical. “Leveraging the differentiated strengths of 바카라 사이트 compared to existing treatments, we aim to enter 100 countries by 2027 and accelerate our pursuit of the ‘1 product, KRW 1 trillion’ goal by 2030,” he added.